Q-omics provides the consensus-scored IDH3B profile across patient tissues and cancer cell-line models. IDH3B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IDH3B is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, IDH3B protein abundance shows 30,107 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where IDH3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IDH3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IDH3B survival associations across molecular data types. IDH3B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IDH3B RNA expression–survival associations across cancer types. High IDH3B expression shows unfavorable associations in UVM, LUAD, LIHC, ESCA and MESO, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IDH3B RNA expression.
This table summarizes IDH3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IDH3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IDH3B shows lower tumor expression in THCA and higher tumor expression in STAD, LIHC, KIRC, HNSC and LUSC. The THCA box plot shows higher IDH3B RNA expression in normal versus tumor tissue (log2 FC = −0.370, t-test p < 0.001).
This table shows molecular features associated with IDH3B in patient tissues and cancer cell lines. In patient samples, IDH3B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IDH3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
